Home > Boards > US Listed > Biotechs >

Regen BioPharma Inc. (RGBP)

Add RGBP Price Alert      Hide Sticky   Hide Intro
Moderator: gotinearly, ronrooster, stockmoneybaby, CrazyKar123
Search This Board: 
Last Post: 10/16/2019 12:02:24 PM - Followers: 390 - Board type: Free - Posts Today: 0


Regen BioPharma 
Followers: 388 Since 8/12/19

 0.0008  Ticker Symbol: RGBP 
Last iBox update 8/17/19 4PM by CrazyKar123



Cell Therapy Technologies Market – Global Industry Insights and Forecast year 2018-2025
SAN DIEGO , Aug. 15, 2019 /PRNewswire/ -- Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP),
Regen BioPharma Inc. Files Immuno-Oncology Patent Application on Synergy of Cannabidiol With NR2F6 Modulation

All other Regen BioPharma News


Regen BioPharma, Inc. 4700 Spring Street, Suite 304
La Mesa, CA 91942 U.S.A.

Telephone: (619) 702-1404
Fax: (619) 330-2328

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).


Product Pipeline | Regen BioPharma, Inc.

Small Molecules Targeting Cancer and Autoimmunity

Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses.
  • Objective is to identify small molecules that can activate and inhibit NR2F6
    ?Currently in pre-clinical development 
    Initial indications (inhibitor): bladder cancer, myelodysplastic syndrome, lung cancer
    Initial indications (activator): rheumatoid arthritis, inflammatory bowel disease, psoriasis
    Additional indications include solid tumors, acute leukemia and GVHD


Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS
HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning.
  • Fat stem cell based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemo, or chronic conditions
    HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow 
    ?United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376)



Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”
  • 10 advanced breast cancer patients
    Efficacy endpoints at 6 and 12 months
    Establishment of safety will allow for rapid expansion of patient numbers 
    Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program 



Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.
  • siRNA silencing of our newly discovered cancer stem cell target gene
    Silencing using DiffronC induces differentiation of cancer cells 
    Initial indication is treatment of myelodysplastic syndrome 
    Other indications include solid tumors and acute leukemia


Telomeres & Genomic Integrity

Stem cells and cancer cells have found ways of maintaining their telomeres in a state that prevents senescence. Our research in to the cancer stem cell has given us a molecular pathway that can be manipulated to expand stem cells and maintain telomeres.
  • Telomeres are protective structures at the ends of chromosomes that enable cell divisions
    Telomere attrition is involved in aging, cancer and genetic mutations 
    We are developing drugs that modulate telomere maintenance 
    In pre-clinical development for indications of solid cancers and acute leukemia

Image result for cbd


Regen BioPharma, Inc. Examines Combining Cannabidiol (CBD) With Its Lead NR2F6 Agonist To Treat for Inflammatory Bowel Disease


SAN DIEGO, January 8, 2019 /PRNewswire/ --   https://www.otcmarkets.com/stock/RGBP/news/Regen-BioPharma-Inc-Examines-Combining-Cannabidiol-CBD-With-Its-Lead-NR2F6-Agonist-To-Treat-for-Inflammatory-Bowel-Disea?id=214869

Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have determined that combining its lead NR2F6 small molecule agonist with Cannabidiol (CBD) may provide a dynamic therapy for treating inflammatory bowel disease (IBD). Currently, there are a number of pre-clinical and clinical studies being conducted by other companies regarding pain management that suggest potential benefits of CBD. Regen believes that CBD may augment the Company's small molecule therapies for autoimmune disorders, in this case specifically IBD.

IBD is a disease caused by persistent and chronic inflammation of the gastrointestinal tract and is a term that refers to both ulcerative colitis and Crohn's disease. Current treatments include non-specific immune suppressors such as steroids as well as newer drugs recently approved by the FDA. The IBD market size is estimated at $6.7 billion global and projected to be $7.6 billion by 2023.There are currently no non-steroidal therapies  available to IBD sufferers.

"Our ex-vivo studies with RG-NAH005 (Regen's small molecule agonist) support moving the drug into animal studies where we can measure the effect of the drug on different diseases," says Harry Lander, Ph.D., President and Chief Scientific Officer of Regen.  "We believe incorporating CBD in our studies will allow us to potentially strengthen positive outcomes for patients."

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity and chronic inflammation.

"We are pleased that RG-NAH005 has shown a safety profile that allows us to move it into animal studies," says David Koos, Ph.D., Chairman & CEO of both Regen BioPharma, Inc. and Zander Therapeutics, Inc. "We are enthusiastic that combining CBD with our small molecule agonist will potentially make our small molecule therapy for IBD more dynamic is its approach to treating this disease."



Always research for yourself BEFORE you buy in the OTC !!!!

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#37075  Sticky Note Value of RGBP will be revealed very soon.See ronrooster 10/12/19 01:51:19 PM
#36855  Sticky Note Regen Biopharma Inc ( RGBP ) .0014 CrazyKar123 08/18/19 02:23:05 PM
#27909  Sticky Note ELI LILLY HAS RGBP SCREENING COMPOUNDS FOR THEM!!!!!!!!!!! gotinearly 06/30/16 09:23:49 AM
#37080   I don t understand why you say..."giving up"... annarita1974 10/16/19 12:02:23 PM
#37079   Assuming all saw this (From CrazyC's post on LaddyMan 10/16/19 11:11:28 AM
#37076   What's good for the KOOS is good for sizzleweed 10/14/19 12:56:42 PM
#37075   Value of RGBP will be revealed very soon.See ronrooster 10/12/19 01:51:19 PM
#37074   I like to read what the common post Mikemcl 10/11/19 01:24:57 PM
#37073   Did koos cure Ebola yet? Lol SidVicious 10/11/19 08:23:16 AM
#37071   They all have pretty well disappeared .Trip 1 ronrooster 10/10/19 04:17:46 PM
#37070   Yup gotinearly 10/10/19 01:44:49 PM
#37069   You always have to take notes on the Midnight pumper 10/10/19 01:43:48 PM
#37068   notice who is now gone... gotinearly 10/10/19 01:42:57 PM
#37067   Rgbp definitely has a ton of note holders.Price ronrooster 10/10/19 12:06:58 PM
#37066   you are absolutely correct. no painting today gotinearly 10/10/19 11:51:49 AM
#37065   I guess it depends on how you look ronrooster 10/10/19 09:45:03 AM
#37064   It Is Being Manipulated Down. They Keep Paint $avvyPenny$tockInvestor™ 10/10/19 06:18:22 AM
#37063   10 paint ups to .001 today.stock is being ronrooster 10/09/19 04:34:56 PM
#37062   It's all good my friend. That's the PRIVATE SHAREHOLDER 10/09/19 04:03:52 PM
#37061   Right, but I hate how they are manipulating $avvyPenny$tockInvestor™ 10/09/19 03:34:19 PM
#37060   Absolutely! Patience can be rewarded. PRIVATE SHAREHOLDER 10/09/19 03:33:17 PM
#37059   You still holding? $avvyPenny$tockInvestor™ 10/09/19 03:30:21 PM
#37058   You see this manipulation bro? $avvyPenny$tockInvestor™ 10/09/19 11:31:59 AM
#37057   Someone is manipulating to load. $avvyPenny$tockInvestor™ 10/09/19 11:31:44 AM
#37056   In order to get some cheap shares, the ronrooster 10/08/19 01:19:13 PM
#37055   Reverse Merger coming soon? TYackys 10/08/19 08:17:32 AM
#37054   Yes in a couple of weeks a new SanDiegoAlan 10/07/19 06:01:12 PM
#37053   Big News on Pending TYackys 10/07/19 04:34:11 PM
#37052   Yep! Someone Needs To Slap The Ask And $avvyPenny$tockInvestor™ 10/07/19 11:43:19 AM
#37051   Big time sexysamir 10/07/19 11:28:10 AM
#37050   Right, Someone Is Quietly Loading! $avvyPenny$tockInvestor™ 10/07/19 11:17:43 AM
#37049   RGBP/ Strong Buy TYackys 10/07/19 10:25:46 AM
#37048   RGBP / Pennyland soon TYackys 10/07/19 10:25:00 AM
#37047   We will See here Big Runner TYackys 10/05/19 06:42:47 PM
#37046   Agreed 100% TYackys 10/05/19 06:41:53 PM
#37045   ENTB, BMSN, RGBP. I see a pattern Natureboy1 10/05/19 05:48:11 PM
#37044   Current Market Cap of Regen (including prefered shares) ronrooster 10/05/19 03:33:05 PM
#37043   RGBP / Great & Strong / Pennyland Soon $$$$ TYackys 10/05/19 11:45:13 AM
#37042   Right, This Was Intentionally Held Down...It Was Crazy. $avvyPenny$tockInvestor™ 10/05/19 10:23:20 AM
#37041   I'm surprised it wasn't up there yesterday. Lucky Fireindahole101 10/05/19 09:47:14 AM
#37040   #9 Breakout Board Aarons 10/05/19 04:35:10 AM
#37039   Will Adding More; Definetly On Long Term Target TYackys 10/05/19 02:49:38 AM
#37038   Was trying to use reverse psych. It worked. TheAnnointedOne 10/04/19 08:18:00 PM
#37037   RGBP / Strong Buy $$$$$ TYackys 10/04/19 07:53:12 PM
#37036   RGBP Pennyland soon TYackys 10/04/19 07:52:27 PM
#37035   You're delusional. Keep trying! PRIVATE SHAREHOLDER 10/04/19 05:54:14 PM
#37034   THERE IS NO DILUTION!!! SO Constant PAINTING THE $avvyPenny$tockInvestor™ 10/04/19 04:06:32 PM
#37033   Bro..you can see the manipulation. They keep painting $avvyPenny$tockInvestor™ 10/04/19 03:51:23 PM
#37032   Right! Patience! $avvyPenny$tockInvestor™ 10/04/19 03:46:33 PM
#37031   There Is No Dilutive MM's bro. Nice try! $avvyPenny$tockInvestor™ 10/04/19 03:34:16 PM
#37030   Massive dilution starkd748 10/04/19 03:13:10 PM
#37029   You are right sir! Aarons 10/04/19 03:07:05 PM
#37028   Aarons 10/04/19 03:06:17 PM